Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT05415410 |
| Consolidated Lead Sponsor | VectivBio AG |
| Therapeutic Condition Cohort | Immunology, Rheumatology, and Dermatology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | TERMINATED |
| Registered Enrollment | 31 participants (ACTUAL) |
| Registered Start Date | 2022-05-25 |
| WhyStopped Classification | Strategic / Business / Sponsor Decision |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Stanford Health Care and Stanford Cancer Institute | Stanford, CA | Open Hospital Dossier -> |
| University of Iowa | Iowa City, IA | Open Hospital Dossier -> |
| Massachusetts General Hospital | Boston, MA | Open Hospital Dossier -> |
| Ohio State University Comprehensive Cancer Center | Columbus, OH | Open Hospital Dossier -> |
Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.